Personalized therapy for breast cancer

Clinical Genetics

Volumn 86, Issue 1, 2014, Pages 62-67

  De Abreu, F B ^a   Schwartz, G N ^a,b   Wells, W A ^a   Tsongalis, G J ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Breast cancer; Molecular oncology; Personalized medicine; Pharmacogenomics

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LAPATINIB; LASOFOXIFENE; LETROZOLE; PERTUZUMAB; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; BIOLOGICAL MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CLINICAL DECISION MAKING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENOMICS; HUMAN; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TRANSCRIPTOMICS; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CLASSIFICATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; PROCEDURES; PROGNOSIS; TRENDS;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PROGNOSIS;

EID: 84901690633     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12381     Document Type: Review

References (33)

1. Allison KH. Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol 2012: 138: 770-780.
2. Gonzalez-Augulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010: 28: 2777-2783.
3. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000: 406: 747-752.
4. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006: 7: 96.
5. Herschkowitz JI, Simin K, Weigman VJ et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007: 8: R76.
6. Rivenbark AG, O'Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol 2013: 183: 1113-1124.
7. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 2006: 11: 868-877.
8. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012: 38: 698-707.
9. Snoj N, Dinh P, Bedard P, Sotiriou C. Molecular biology of breast cancer. In: Coleman WB, Tsongalis GJ, eds. Essential concepts in molecular pathology. San Diego, CA: Elsevier Press, 2012: 341-349.
10. Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 2013: 133: 1-13.
11. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005: 97: 1652-1662.
12. Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007: 99: 272-282.
13. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 2011: 378: 771-784.
14. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999: 353: 1993-2000.
15. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001: 28: 400-418.
16. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999: 281: 2189-2197.
17. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004: 96: 1751-1761.
18. Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006: 355: 125-137.
19. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006: 295: 2727-2741.
20. Cummings SR, Ensrud K, Delmas PD et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010: 362: 686-696.
21. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol 2013: 3: 250e.
22. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (Arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003: 163: 96-103.
23. Goss PE, Richardson H, Chlebowski R et al. National Cancer Institute of Canada ClinicalTrialsGroupMAP.3 trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 2007: 7: 895-900.
24. Goss PE, Ingle JN, Ales-Martinez JE et al. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011: 364: 2381-2391.
25. Cuzick J, Sestak I, Forbes JF et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014: 383: 1041-1048.
26. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010: 28: 1124-1130.
27. Mohamed A, Krajewski K, Cakar B, Ma CX. Targeted therapy for breast cancer. Am J Pathol 2013: 183: 1096-1112.
28. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012: 367: 1783-1791.
29. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011: 121: 2750-2767.
30. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010: 36: 206-215.
31. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009: 27: 1160-1167.
32. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010: 12: R68.
33. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006: 98: 262-272.